The Effect of Donation Frequency on Donor Health in Blood Donors Donating Plasma by Plasmapheresis: Study Protocol for a Randomized Controlled Trial

Overview

Journal Trials

Publisher Biomed Central

Specialties General Medicine
Pharmacology

Date 2024 Mar 12

PMID 38468338

Authors

Morten Haugen

Karin Magnussen

Tonje Eiane Aarsland

Lise Sofie Haug Nissen-Meyer

Tor A Strand

Affiliations

Soon will be listed here.

Abstract

Background: The demand for plasma products is growing, necessitating an increase in plasma collection by plasmapheresis. While the 20th edition of the European Guidelines permits plasma donors in Europe to donate with 96-h donation intervals, the potential short- and long-term consequences of high-frequency plasma donations on donor health remain unknown. This study aims to measure the effect of plasma donation frequency on plasma protein composition, including total serum protein (TSP) and immunoglobulin G (IgG), in Norwegian male blood donors.

Methods: This randomized controlled trial (RCT) included 120 male blood donors who were randomized into two intervention groups and one control group: high-frequency plasma donors (HFPDs) who donated 650 mL of plasma 3 times every 2 weeks, whereas regular-frequency plasma donors (RFPDs) who donated 650 mL of plasma 1 time every 2 weeks. The control group consisted of whole blood donors. The primary outcomes are the concentrations of TSP and IgG.

Discussion: The findings from this study may have implications for recommendations related to donor health and plasma donation frequencies and may contribute to supporting the strategic independence of plasma products in Norway and Europe without compromising donor health.

Trial Registration: ClinicalTrials.gov: NCT05179200 . Registered December 20th, 2021.

References

Lewis S, Kutvirt S, Bonner P, Simon T . Plasma proteins and lymphocyte phenotypes in long-term plasma donors. Transfusion. 1994; 34(7):578-85. DOI: 10.1046/j.1537-2995.1994.34794330011.x. View

Tiberghien P . Increasing unpaid plasma collection by blood establishments to ensure availability of plasma-derived medicinal products and blood components in Europe. Transfus Clin Biol. 2021; 28(4):331-333. DOI: 10.1016/j.tracli.2021.09.004. View

Malangwa G, Mangi E . Psychological Distress Factors among Caregivers of Children Receiving Cancer Therapy, at Muhimbili National Hospital. East Afr Health Res J. 2022; 6(1):70-77. PMC: 9639614. DOI: 10.24248/eahrj.v6i1.681. View

Burnouf T . Modern plasma fractionation. Transfus Med Rev. 2007; 21(2):101-17. PMC: 7125842. DOI: 10.1016/j.tmrv.2006.11.001. View

Rosa-Bray M, Wisdom C, Wada S, Johnson B, Grifols-Roura V, Grifols-Lucas V . Prospective multicentre study of the effect of voluntary plasmapheresis on plasma cholesterol levels in donors. Vox Sang. 2013; 105(2):108-15. PMC: 3813983. DOI: 10.1111/vox.12031. View

Atsma F, de Vegt F . The healthy donor effect: a matter of selection bias and confounding. Transfusion. 2011; 51(9):1883-5. DOI: 10.1111/j.1537-2995.2011.03270.x. View

Ciszewski T, Ralston S, Acteson D, Wasi S, Strong S . Protein levels and plasmapheresis intensity. Transfus Med. 1993; 3(1):59-65. DOI: 10.1111/j.1365-3148.1993.tb00105.x. View

. Uniform requirements for manuscripts submitted to biomedical journals: Writing and editing for biomedical publication. J Pharmacol Pharmacother. 2011; 1(1):42-58. PMC: 3142758. View

Veijola J, Jokelainen J, Laksy K, Kantojarvi L, Kokkonen P, Jarvelin M . The Hopkins Symptom Checklist-25 in screening DSM-III-R axis-I disorders. Nord J Psychiatry. 2003; 57(2):119-23. DOI: 10.1080/08039480310000941. View

10.

Lamb M . Source plasma: future outlook. Transfusion. 2009; 49(7 Pt 2):1520-6. DOI: 10.1111/j.1537-2995.2009.02264.x. View

11.

Shanbrom E, Lundak R, WALFORD R . Long-term plasmapheresis: effects on specific plasma proteins. Transfusion. 1972; 12(3):162-7. DOI: 10.1111/j.1537-2995.1972.tb00003.x. View

12.

Knapstad M, Sivertsen B, Knudsen A, Smith O, Aaro L, Lonning K . Trends in self-reported psychological distress among college and university students from 2010 to 2018. Psychol Med. 2019; 51(3):470-478. PMC: 7958482. DOI: 10.1017/S0033291719003350. View

13.

Lau F, Giugliano R . Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review. JAMA Cardiol. 2022; 7(7):760-769. DOI: 10.1001/jamacardio.2022.0987. View

14.

Townsend M, Kamel H, Van Buren N, Wiersum-Osselton J, Rosa-Bray M, Gottschall J . Development and validation of donor adverse reaction severity grading tool: enhancing objective grade assignment to donor adverse events. Transfusion. 2020; 60(6):1231-1242. DOI: 10.1111/trf.15830. View

15.

Tran-Mi B, Storch H, Seidel K, Schulzki T, Haubelt H, Anders C . The impact of different intensities of regular donor plasmapheresis on humoral and cellular immunity, red cell and iron metabolism, and cardiovascular risk markers. Vox Sang. 2004; 86(3):189-97. DOI: 10.1111/j.0042-9007.2004.00408.x. View

16.

Goldman M, Land K, Robillard P, Wiersum-Osselton J . Development of standard definitions for surveillance of complications related to blood donation. Vox Sang. 2015; 110(2):185-8. DOI: 10.1111/vox.12323. View

17.

Cohen M, OBERMAN H . Safety and long-term effects of plasmapheresis. Transfusion. 1970; 10(2):58-66. DOI: 10.1111/j.1537-2995.1970.tb00706.x. View

18.

Brodersen T, Rostgaard K, Lau C, Juel K, Erikstrup C, Nielsen K . The healthy donor effect and survey participation, becoming a donor and donor career. Transfusion. 2022; 63(1):143-155. PMC: 10107247. DOI: 10.1111/trf.17190. View

19.

Friedman B, Schork M, Mocniak J, OBERMAN H . Short-term and long-term effects of plasmapheresis on serum proteins and immunoglobulins. Transfusion. 1975; 15(5):467-72. DOI: 10.1046/j.1537-2995.1975.15576082222.x. View

20.

Schulzki T, Seidel K, Storch H, Karges H, Kiessig S, Schneider S . A prospective multicentre study on the safety of long-term intensive plasmapheresis in donors (SIPLA). Vox Sang. 2006; 91(2):162-73. DOI: 10.1111/j.1423-0410.2006.00794.x. View